Academia.edu no longer supports Internet Explorer.
To browse Academia.edu and the wider internet faster and more securely, please take a few seconds to upgrade your browser.
2010, Cancer Treatment Reviews
Medical Oncology
Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib2012 •
2013 •
Sorafenib is a multi-targeted tyrosine kinase receptor inhibitor used to treat patients with advanced gastrointestinal stromal tumors (GISTs). The present study evaluated the efficacy and tolerability of sorafenib therapy for patients with GISTs. Between January 2001 and November 2012, 25 patients, from multiple centers, who had received sorafenib as the third- or fourth-line treatment for GISTs were investigated retrospectively. In total, 17 patients were male and eight were female. The median age was 54.0 years (range, 16-82 years). From the patients, 21 received imatinib for longer than six months and four received it for less than six months. The clinical benefit rate of sorafenib was 40.0%. Treatment-related adverse events were reported in 72% of patients. These adverse events were generally mild to moderate in intensity. The median progression-free survival (PFS) and overall survival (OS) times of the patients who received sorafenib were 7.2 and 15.2 months, respectively. The ...
Case Reports in Oncology
Outstanding Response to Sorafenib in a Patient with Metastatic Gastrointestinal Stromal Tumour2021 •
Gastrointestinal stromal tumour (GIST) is the most common sarcoma and can be seen in any part of the gastrointestinal tract. The effect of tyrosine kinase inhibitors varies with mutation status in receptor tyrosine kinase KIT and in platelet-derived growth factor receptor A (PDGFRA). This case presents a 61-year-old man, diagnosed with an 11-cm GIST located at the stomach with a high risk of recurrence. The patient showed intolerance to imatinib shortly after introduction and subsequently progressed on sunitinib and nilotinib. The patient started fourth-line treatment with sorafenib with an impressive response to a point at which metastases intra-abdominally and in the liver could be resected. After surgery, sorafenib was restarted. Due to toxicity, sorafenib dose was reduced over time. The dose was insufficient to control the disease since a new recurrence was detected. Mutation analyses revealed a GIST harbouring a deletion of codon p.I843_D846del, located at PDGFRA exon 18, right...
2006 •
2007 •
Clinical Lung Cancer
2002 Highlights From: 27th Congress of the European Society for Medical Oncology; Nice, France October 18–22, 20022002 •
Biomedical Journal of Scientific & Technical Research
Tumor Response and Factors Affecting Survival of Using Sorafenib in Management of Advanced Hepatocellular Carcinoma2021 •
2007 •
2013 •
Revista Kamchatka
TOPOGRAFÍAS DE LA MEMORIA: Monográfico coordinado por MARISA GONZÁLEZ DE OLEAGA Y CAROLINA MELONI2019 •
2006 •
Clinical Drug Investigation
Efficacy of Off-Label Topical Treatments for the Management of Androgenetic Alopecia: A Review2019 •
2019 •
Southwestern Entomologist
The Invasive Gall Wasp Quadrastichus erythrinae Kim in Mexico2017 •
Kunstschrift 36:4
'Harold Rosenberg: het schilderij als een arena' (Harold Rosenberg: the painting as an arena)1992 •
Jurnal Abdimas Indonesia
Penyuluhan Pengelolaan Dan Pengolahan Sampah Berbasis Limbah Organik Rumah Tangga Sebagai Produk Eco-Enzym2024 •
2017 •
2018 •
Vegetable Science
Quality and nutritional composition in tomato fruit at different stages of maturity2017 •
Multimedia Tools and Applications
Video expert assessment of high quality video for Video Assistant Referee (VAR): A comparative study2023 •
2020 •
T&T Clark eBooks
What’s in a Name?: Ideologies of Volk, Rasse, and Reich in German New Testament Interpretation Past and Present2018 •
Angewandte Chemie (International ed. in English)
An Efficient Anti-poisoning catalyst against SOx, NOx and POx: P, N- doped Carbon for Oxygen Reduction in Acidic Media2018 •